Solid Biosciences’ (SLDB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a research note released on Monday,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Solid Biosciences’ Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.81 EPS.

Several other research analysts have also recently weighed in on SLDB. Wedbush restated an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a report on Wednesday, March 11th. Chardan Capital reissued a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Friday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research note on Friday, March 20th. Guggenheim assumed coverage on Solid Biosciences in a report on Friday, March 20th. They issued a “buy” rating and a $26.00 target price for the company. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.09.

Solid Biosciences Trading Up 8.2%

Shares of NASDAQ:SLDB opened at $7.23 on Monday. The stock has a market cap of $563.29 million, a PE ratio of -3.58 and a beta of 2.65. The stock’s fifty day simple moving average is $6.53 and its two-hundred day simple moving average is $5.82. Solid Biosciences has a 1-year low of $2.41 and a 1-year high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, sell-side analysts forecast that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, CFO Kevin Tan sold 5,404 shares of Solid Biosciences stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total value of $31,451.28. Following the sale, the chief financial officer owned 99,422 shares of the company’s stock, valued at approximately $578,636.04. The trade was a 5.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO David T. Howton sold 7,469 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total transaction of $43,469.58. Following the completion of the transaction, the chief operating officer owned 105,077 shares in the company, valued at approximately $611,548.14. The trade was a 6.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 597,672 shares of company stock valued at $3,816,546 in the last three months. 1.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Solid Biosciences

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc grew its holdings in Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after purchasing an additional 4,063 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Solid Biosciences by 205.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after buying an additional 4,534 shares during the last quarter. Creative Planning bought a new position in shares of Solid Biosciences during the 2nd quarter worth $57,000. Russell Investments Group Ltd. grew its stake in shares of Solid Biosciences by 142.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after acquiring an additional 5,991 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in Solid Biosciences by 233.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after acquiring an additional 10,585 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Key Stories Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on SLDB to $12.00 from $11.00 and moved the stock to an “Overweight” stance — implying roughly a 66% upside from the referenced $7.23 level. This upgrade signals increased conviction from a large Wall Street shop and likely contributed to buying interest. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted near-term EPS forecasts across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026) while maintaining a $20 price target. They also issued later-year upside (FY2029–FY2030 projected profitability), trimming FY2026 losses significantly vs. prior forecasts — an analyst view that supports a more constructive growth/profitability outlook. Solid Biosciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Reported short-interest data for March appears anomalous (shows 0 shares and NaN changes). Because the figures are likely erroneous or incomplete, they provide no clear signal about potential short-squeeze dynamics or bearish positioning at this time.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical?stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle?stabilizing protein.

Solid’s lead investigational therapy, SGT?001, is a micro?dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno?associated virus (AAV) vector.